Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 12/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106078 | 1.00 | MAPT (0.46) | MAPTSMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL4009582 | 0.91 | MCHR1 (0.45) | MAPTSMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL4009588 | 0.91 | MCHR1 (0.45) | MAPTSMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL4010216 | 0.91 | MAPT (0.45) | MAPTSMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL5108453 | 0.91 | MAPT (0.45) | MAPTSMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL14209944 | 0.89 | MAPT (0.49) | MAPTSMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL5108851 | 0.84 | MAPT (0.43) | MAPTSMN1; SMN2MEN1KMT2AMCHR1 | |
| SCHEMBL4015372 | 0.84 | MAPT (0.43) | MAPTSMN1; SMN2MEN1KMT2AMCHR1 | |
| SCHEMBL5115620 | 0.84 | ALDH1A1 (0.45) | MAPTSMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL4011356 | 0.84 | ALDH1A1 (0.45) | MAPTSMN1; SMN2MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558567-B1 | NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-06-24 | — | — | EP | disclosed |
| US-7351719-B2 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-04-01 | — | — | US | disclosed |
| US-7351719-B2 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-04-01 | — | — | US | disclosed |
| US-7351719-B2 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-04-01 | — | — | US | disclosed |
| CN-1708476-A | Novel amide compounds having MCH-antagonistic action and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-12-14 | — | — | CN | disclosed |
| US-20040152742-A1 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152742-A1 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | MCHR2, MCHR1, NPY1R | MAPT 4346/4885SMN1; SMN2 2811/4885MEN1 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.